Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Dabrafenib With RAI for Refractory Metastatic Differentiated Thyroid Cancer
NCT03244956Phase 2Completed
- Sponsor
- Gustave Roussy
- Start
- Dec 2017
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib and dabrafenib + trametinib in thyroid cancer (2 arms), sponsored by Gustave Roussy. Primary endpoint: Objective Response Rate at 6 months. Started Dec 2017; status: completed.
02
Drugs
trametinibdabrafenib + trametinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT03244956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03244956.